Sudarshan Pharma shares: Up 30% in 2026 so far! Will it rebound after profit-booking trigger? Experts' views, target, SL

The stock rose over the last three sessions ahead of the Q2 results announcement. The company's Q2FY numbers came in line with market estimates, triggering profit-booking in the scrip. So, one should view this as the market's rebalancing after a strong uptrend. However, they gave some credit to the stock rally for the mainboard listing from the BSE SME platform.Sudarshan Pharma Q2 Results 2026Speaking on the Q2 Results 2026 of Sudarshan Pharma Industries, Anuj Gupta, a SEBI-registered market expert, said, “The pharma company reported strong YoY growth for Q2 FY27, with net profit surging 86% to around ₹7.78 crore and revenue jumping 28%.”A key highlight of the quarterly performance was the significant improvement in profitability, with net profit growing at more than three times the rate of revenue in percentage terms.

The company’s net profit margin expanded to 3.6% from 2.5% a year earlier, indicating improved earnings efficiency.The latest results demonstrate strengthening operational performance, supported by higher revenue generation and better profit conversion. The company recorded an additional ₹48.10 crore in quarterly revenue, while net profit increased by ₹3.60 crore compared with the corresponding period last year.The SEBI-registered expert said that despite the strong performance, the stock dropped after inching close to the 52-week high, as investors engaged in profit-booking following a strong prior run-up and amid concerns over the stock's premium valuation and interest-cost burdens.

He said that Sudarshan Pharma shares have become a mainboard stock after listing on the NSE on 27th October 2026, and some credit for the successive rally goes to the stock's journey from a BSE SME to a mainboard stock.Sudarshan Pharma share price targetDecoding the technical chart of Sudarshan PPharma Industries shares, Mahesh M Ojha, VP - Research and Business Development at KC Securities, said, “Existing shareholders are advised to hold the scrip, maintaining a strict stop-loss at ₹31.80 apiece.

The stock may deliver significant upside once it closes above ₹37. A breakout above ₹37 means a fresh upside with a target price of ₹48.”On suggestion to the fresh investors, the KC Securities expert said that fresh entry is advised only above the ₹37 breakout. Once the stock breaks out above ₹37, a fresh entry is advised with a stop-loss at ₹31.80, targeting ₹42 and ₹48 in the short to medium term.Disclaimer: This story is for educational and informational purposes only.

The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified financial experts before making any investment decisions.